Moderna Reports Phase 3 Success in Cancer Vaccine Trial Amid Industry Shifts
What happened
Moderna reported outstanding Phase 3 clinical trial results for its mRNA-based cancer vaccine candidate, intismeran autogene, marking one of the first major Phase 3 wins in this area. In contrast, BioNTech has experienced recent clinical setbacks and reported a significant decline in revenue, which dropped almost 60% compared to the previous year. BioNTech's Q2 net loss per share was 3.24 euros, worsening from the 1.60 euros reported in the prior year.
From fool.com
Why it matters
Moderna's clinical success validates the personalized cancer vaccine market, which is currently at an inflection point. This success is relevant to companies like Merck KGaA and Merck, which maintain operational partnerships with Moderna to jointly develop personalized mRNA cancer vaccines.
From fool.com
Who's involved
- ModernaAmerican biotechnology company that posted Phase 3 clinical trial results for a cancer vaccine.
- Merck KGaAGerman multinational science and technology company partnered with Moderna on personalized mRNA cancer vaccines.
- MerckPublic company in Indonesia partnered with Moderna on personalized mRNA cancer vaccines.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Moderna
American biotechnology company
Related events
- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Moderna presented vaccine results at the ESMO meeting in Madrid, with RBC Capital Markets covering the company.
- Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.